Autoreactive B cell responses targeting nuclear antigens in systemic sclerosis: Implications for disease pathogenesis

Allanore, 2015, Systemic sclerosis, Nat Rev Dis Primers, 1, 15002, 10.1038/nrdp.2015.2 Sanges, 2017, Role of B cells in the pathogenesis of systemic sclerosis, La Revue Med Interne, 38, 113, 10.1016/j.revmed.2016.02.016 Steen, 2005, Autoantibodies in systemic sclerosis, Semin Arthritis Rheum, 35, 35, 10.1016/j.semarthrit.2005.03.005 Rubin, 2019, B cell checkpoints in autoimmune rheumatic diseases, Nat Rev Rheumatol, 15, 303, 10.1038/s41584-019-0211-0 Reijm, 2020, Checkpoints controlling the induction of B cell mediated autoimmunity in human autoimmune diseases, Eur J Immunol, 50, 1885, 10.1002/eji.202048820 Nemazee, 2017, Mechanisms of central tolerance for B cells, Nat Rev Immunol, 17, 281, 10.1038/nri.2017.19 Burbelo, 2019, Autoantibodies are present before the clinical diagnosis of systemic sclerosis, PLoS One, 14, 10.1371/journal.pone.0214202 Mehra, 2013, Autoantibodies in systemic sclerosis, Autoimmun Rev, 12, 340, 10.1016/j.autrev.2012.05.011 Stochmal, 2020, Antinuclear antibodies in systemic sclerosis: an update, Clin Rev Allergy Immunol, 58, 40, 10.1007/s12016-018-8718-8 Meyer, 1998, How useful are serum autoantibodies in the diagnosis and prognosis of systemic sclerosis?, Clin Rheumatol, 17, 179, 10.1007/BF01451042 van den Hoogen, 2013, 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative, Arthritis Rheum, 65, 2737, 10.1002/art.38098 Minier, 2014, Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis, Ann Rheum Dis, 73, 2087, 10.1136/annrheumdis-2013-203716 Toltl, 2011, Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters, Br J Haematol, 152, 52, 10.1111/j.1365-2141.2010.08412.x Koneczny, 2019, Myasthenia gravis: pathogenic effects of autoantibodies on neuromuscular architecture, Cells, 8, 671, 10.3390/cells8070671 Derksen, 2017, The role of autoantibodies in the pathophysiology of rheumatoid arthritis, Semin Immunopathol, 39, 437, 10.1007/s00281-017-0627-z Lebwohl, 2018, Coeliac disease, Lancet, 391, 70, 10.1016/S0140-6736(17)31796-8 DiMeglio, 2018, Type 1 diabetes, Lancet, 391, 2449, 10.1016/S0140-6736(18)31320-5 Kristyanto, 2020, Persistently activated, proliferative memory autoreactive B cells promote inflammation in rheumatoid arthritis, Sci Transl Med, 12, 10.1126/scitranslmed.aaz5327 Lee, 2021, B cell depletion therapies in autoimmune disease: advances and mechanistic insights, Nat Rev Drug Discov, 20, 179, 10.1038/s41573-020-00092-2 Elhai, 2012, Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies, Rheumatology, 51, 1017, 10.1093/rheumatology/ker269 Riemekasten, 2011, Involvement of functional autoantibodies against vascular receptors in systemic sclerosis, Ann Rheum Dis, 70, 530, 10.1136/ard.2010.135772 Nihtyanova, 2010, Autoantibodies as predictive tools in systemic sclerosis, Nat Rev Rheumatol, 6, 112, 10.1038/nrrheum.2009.238 Douvas, 1979, Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma, J Biol Chem, 254, 10514, 10.1016/S0021-9258(19)86738-8 Shero, 1986, High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients, Science, 231, 737, 10.1126/science.3003910 Guldner, 1986, Scl 70 autoantibodies from scleroderma patients recognize a 95 kDa protein identified as DNA topoisomerase I, Chromosoma, 94, 132, 10.1007/BF00286991 Earnshaw, 1986, Three human chromosomal autoantigens are recognized by sera from patients with anti-centromere antibodies, J Clin Invest, 77, 426, 10.1172/JCI112320 Hildebrandt, 1990, The IgG, IgM, and IgA isotypes of anti-topoisomerase I and anticentromere autoantibodies, Arthritis Rheum, 33, 724, 10.1002/art.1780330515 Kuwana, 1993, Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis, J Clin Invest, 91, 1399, 10.1172/JCI116343 Okano, 1993, Autoantibody reactive with RNA polymerase III in systemic sclerosis, Ann Intern Med, 119, 1005, 10.7326/0003-4819-119-10-199311150-00007 Arnett, 1996, Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis, Arthritis Rheum, 39, 1151, 10.1002/art.1780390712 Reuter, 1989, Mercuric chloride induces autoantibodies against U3 small nuclear ribonucleoprotein in susceptible mice, Proc Nat Acad Sci USA, 86, 237, 10.1073/pnas.86.1.237 Verheijen, 1994, Screening for autoantibodies to the nucleolar U3- and Th (7-2) ribonucleoproteins in patients' sera using antisense riboprobes, J Immunol Methods, 169, 173, 10.1016/0022-1759(94)90261-5 D'Arpa, 1990, Use of molecular cloning methods to map the distribution of epitopes on topoisomerase I (Scl-70) recognized by sera of scleroderma patients, Arthritis Rheum, 33, 1501, 10.1002/art.1780331007 Kuwana, 1993, Autoantigenic epitopes on DNA topoisomerase I. Clinical and immunogenetic associations in systemic sclerosis, Arthritis Rheum, 36, 1406, 10.1002/art.1780361013 Rizou, 2000, B-Cell epitope mapping of DNA topoisomerase I defines epitopes strongly associated with pulmonary fibrosis in systemic sclerosis, Am J Respir Cell Mol Biol, 22, 344, 10.1165/ajrcmb.22.3.3850 Simon, 2009, Naturally occurring and disease-associated auto-antibodies against topoisomerase I: a fine epitope mapping study in systemic sclerosis and systemic lupus erythematosus, Int Immunol, 21, 415, 10.1093/intimm/dxp008 Piccinini, 1991, An antigenic region of topoisomerase I in DNA polymerase chain reaction-generated fragments recognized by autoantibodies of scleroderma patients, Mol Immunol, 28, 333, 10.1016/0161-5890(91)90145-A Earnshaw, 1987, Molecular cloning of cDNA for CENP-B, the major human centromere autoantigen, J Cell Biol, 104, 817, 10.1083/jcb.104.4.817 Whyte, 1995, Frequency of autoantibodies to a major epitope on the carboxyl terminal fragment of cenp-b in patients with autoimmune disease, Rheumatology, 34, 407, 10.1093/rheumatology/34.5.407 Mahler, 2010, Clinical and serological evaluation of a novel CENP-A peptide based ELISA, Arthritis Res Ther, 12, R99, 10.1186/ar3029 Earnshaw, 1987, Analysis of anticentromere autoantibodies using cloned autoantigen CENP-B, Proc Natl Acad Sci, 84, 4979, 10.1073/pnas.84.14.4979 Akbarali, 2006, Fine specificity mapping of autoantigens targeted by anti-centromere autoantibodies, J Autoimmun, 27, 272, 10.1016/j.jaut.2006.10.001 Muro, 2000, Autoepitopes on autoantigen centromere protein-A (CENP-A) are restricted to the N-terminal region, which has no homology with histone H3, Clin Exp Immunol, 120, 218, 10.1046/j.1365-2249.2000.01189.x Mahler, 2000, Fine-specificity of the anti-CENP-A B-cell autoimmune response, J Mol Med, 78, 460, 10.1007/s001090000128 Mahler, 2001, A population of autoantibodies against a centromere-associated protein A major epitope motif cross-reacts with related cryptic epitopes on other nuclear autoantigens and on the Epstein-Barr nuclear antigen 1, J Mol Med, 79, 722, 10.1007/s001090100258 Kuwana, 2002, Identification of an immunodominant epitope on RNA polymerase III recognized by systemic sclerosis sera: application to enzyme-linked immunosorbent assay, Arthritis Rheum, 46, 2742, 10.1002/art.10521 Kuwana, 1999, Autoantibodies to RNA polymerases recognize multiple subunits and demonstrate cross-reactivity with RNA polymerase complexes, Arthritis Rheum, 42, 275, 10.1002/1529-0131(199902)42:2<275::AID-ANR9>3.0.CO;2-P Lübben, 1994, The specificity of disease-associated anti-fibrillarin autoantibodies compared with that of HgCl2-induced autoantibodies, Mol Biol Rep, 20, 63, 10.1007/BF00996355 Kasturi, 1995, Antifibrillarin autoantibodies present in systemic sclerosis and other connective tissue diseases interact with similar epitopes, J Exp Med, 181, 1027, 10.1084/jem.181.3.1027 Takeuchi, 1995, Analysis of the autoantibody response to fibrillarin in human disease and murine models of autoimmunity, J Immunol, 154, 961, 10.4049/jimmunol.154.2.961 Broen, 2011, Deciphering the genetic background of systemic sclerosis, Expert Rev Clinic Immunol, 7, 449, 10.1586/eci.11.26 Acosta-Herrera, 2021, Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes, Ann Rheum Dis, 80, 1040, 10.1136/annrheumdis-2021-219884 Reveille, 2003, Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies, Arthritis Rheum, 49, 399, 10.1002/art.11113 Van Eenennaam, 2002, Autoantibodies against small nucleolar ribonucleoprotein complexes and their clinical associations, Clin Exp Immunol, 130, 532, 10.1046/j.1365-2249.2002.01991.x Mahler, 2010, Anti-Scl-70 (topo-I) antibodies in SLE: myth or reality?, Autoimmun Rev, 9, 756, 10.1016/j.autrev.2010.06.005 Gussin, 2001, Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus, Arthritis Rheum, 44, 376, 10.1002/1529-0131(200102)44:2<376::AID-ANR56>3.0.CO;2-2 Respaldiza, 2006, Anti-centromere antibodies in patients with systemic lupus erythematosus, Scand J Rheumatol, 35, 290, 10.1080/03009740600588376 Russo, 2000, Circulating anticentromere CENP-A and CENP-B antibodies in patients with diffuse and limited systemic sclerosis, systemic lupus erythematosus, and rheumatoid arthritis, J Rheumatol, 27, 142 Bournia, 2010, Anticentromere antibody positive Sjögren's Syndrome: a retrospective descriptive analysis, Arthritis Res Ther, 12, R47, 10.1186/ar2958 Kajio, 2021, Anti-centromere antibodies target centromere-kinetochore macrocomplex: a comprehensive autoantigen profiling, Ann Rheum Dis, 80, 651, 10.1136/annrheumdis-2020-218881 Baer, 2016, Association of Anticentromere Antibodies With More Severe Exocrine Glandular Dysfunction in Sjögren's Syndrome: analysis of the Sjögren's International Collaborative Clinical Alliance Cohort, Arthritis Care Res, 68, 1554, 10.1002/acr.22859 Arbuckle, 2003, Development of autoantibodies before the clinical onset of systemic lupus erythematosus, N Engl J Med, 349, 1526, 10.1056/NEJMoa021933 Scherer, 2018, The B cell response to citrullinated antigens in the development of rheumatoid arthritis, Nat Rev Rheumatol, 14, 157, 10.1038/nrrheum.2018.10 1980, Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee, Arthritis Rheum, 23, 581 LeRoy, 2001, Criteria for the classification of early systemic sclerosis, J Rheumatol, 28, 1573 van den Hoogen, 2013, 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against rheumatism collaborative initiative, Ann Rheum Dis, 72, 1747, 10.1136/annrheumdis-2013-204424 Avouac, 2011, Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group, Ann Rheum Dis, 70, 476, 10.1136/ard.2010.136929 Lee, 1993, Anticentromere antibodies in subjects with no apparent connective tissue disease, Ann Rheum Dis, 52, 586, 10.1136/ard.52.8.586 van Leeuwen, 2021, Anti-centromere antibody levels and isotypes and the development of systemic sclerosis, Arthritis Rheumatol, 10.1002/art.41814 Koenig, 2008, Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis, Arthritis Rheum, 58, 3902, 10.1002/art.24038 Weiner, 1991, Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease. A prospective study, Arthritis Rheum, 34, 68, 10.1002/art.1780340111 Valentini, 2014, Early systemic sclerosis: analysis of the disease course in patients with marker autoantibody and/or capillaroscopic positivity, Arthritis Care Res, 66, 1520, 10.1002/acr.22304 Bellando-Randone, 2021, Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS), Lancet Rheumatol, 3, e834, 10.1016/S2665-9913(21)00244-7 Vázquez-Abad, 1995, Autoantibodies in systemic sclerosis, Int Rev Immunol, 12, 145, 10.3109/08830189509056709 Dick, 2002, Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis, Ann Rheum Dis, 61, 121, 10.1136/ard.61.2.121 Heijnen, 2013, Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR group-based study, Clin Exp Rheumatol, 31, 96 Meijs, 2016, Therapeutic and diagnostic outcomes of a standardised, comprehensive care pathway for patients with systemic sclerosis, RMD Open, 2, 10.1136/rmdopen-2015-000159 Clark, 2022, Combinations of scleroderma hallmark autoantibodies associate with distinct clinical phenotypes, Sci Rep, 12, 11212, 10.1038/s41598-022-15062-4 Tormey, 2001, Anti-fibrillarin antibodies in systemic sclerosis, Rheumatology, 40, 1157, 10.1093/rheumatology/40.10.1157 Hesselstrand, 2003, The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis, Rheumatology, 42, 534, 10.1093/rheumatology/keg170 Walker, 2007, Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database, Ann Rheum Dis, 66, 754, 10.1136/ard.2006.062901 Sobanski, 2019, Phenotypes determined by cluster analysis and their survival in the prospective european scleroderma trials and research cohort of patients with systemic sclerosis, Arthritis Rheumatol, 71, 1553, 10.1002/art.40906 Patterson, 2015, Interpretation of an extended autoantibody profile in a well-characterized australian systemic sclerosis (scleroderma) cohort using principal components analysis, Arthritis Rheumatol, 67, 3234, 10.1002/art.39316 van Leeuwen, 2020, Association between centromere and topoisomerase specific immune responses and the degree of microangiopathy in systemic sclerosis, J Rheumatol Nihtyanova, 2020, Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis, Arthritis Rheumatol, 72, 465, 10.1002/art.41153 Ho, 2003, The clinical relevance of autoantibodies in scleroderma, Arthritis Res Ther, 5, 80, 10.1186/ar628 Liaskos, 2017, Disease-related autoantibody profile in patients with systemic sclerosis, Autoimmunity, 50, 414, 10.1080/08916934.2017.1357699 Hao, 2017, Early mortality in a multinational systemic sclerosis inception cohort, Arthritis Rheumatol, 69, 1067, 10.1002/art.40027 Lazzaroni, 2017, Malignancies in patients with Anti-RNA polymerase III antibodies and systemic sclerosis: analysis of the EULAR scleroderma trials and research cohort and possible recommendations for screening, J Rheumatol, 44, 639, 10.3899/jrheum.160817 Mierau, 2011, Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features, Arthritis Res Ther, 13, R172, 10.1186/ar3495 Hamaguchi, 2008, The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis, Br J Dermatol, 158, 487, 10.1111/j.1365-2133.2007.08392.x Denton, 2017, Systemic sclerosis, Lancet, 390, 1685, 10.1016/S0140-6736(17)30933-9 Homer, 2020, Performance of anti-topoisomerase I antibody testing by multiple-bead, enzyme-linked immunosorbent assay and immunodiffusion in a university setting, J Clin Rheumatol, 26, 115, 10.1097/RHU.0000000000000971 Lam, 2022, False positive anti-topoisomerase I (Scl-70) antibody results in clinical practice: a case series from a scleroderma referral center, Semin Arthritis Rheum, 56, 10.1016/j.semarthrit.2022.152052 Choi, 2019, Autoantibodies in SLE: prediction and the p value matrix, Lupus, 28, 1285, 10.1177/0961203319868531 Chighizola, 2015, Update on the pathogenesis and treatment of the antiphospholipid syndrome, Curr Opin Rheumatol, 27, 476, 10.1097/BOR.0000000000000200 Nocturne, 2013, Advances in understanding the pathogenesis of primary Sjögren's syndrome, Nat Rev Rheumatol, 9, 544, 10.1038/nrrheum.2013.110 Han, 2003, Serial ANCA titers: useful tool for prevention of relapses in ANCA-associated vasculitis, Kidney Int, 63, 1079, 10.1046/j.1523-1755.2003.00821.x Tramposch, 1984, A long-term longitudinal study of anticentromere antibodies, Arthritis Rheum, 27, 121, 10.1002/art.1780270201 Vazquez-Abad, 1995, Longitudinal study of anticentromere and antitopoisomerase-I isotypes, Clin Immunol Immunopathol, 74, 257, 10.1006/clin.1995.1038 Kuwana, 2000, Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis, Arthritis Rheum, 43, 1074, 10.1002/1529-0131(200005)43:5<1074::AID-ANR18>3.0.CO;2-E Hu, 2003, Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis, Arthritis Rheum, 48, 1363, 10.1002/art.10977 Perera, 2007, Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody, Arthritis Rheum, 56, 2740, 10.1002/art.22747 Hasegawa, 2013, Anti-topoisomerase I antibody levels as serum markers of skin sclerosis in systemic sclerosis, J Dermatol, 40, 89, 10.1111/1346-8138.12030 Boonstra, 2020, Association of anti-topoisomerase I antibodies of the IgM isotype with disease progression in anti-topoisomerase I-positive systemic sclerosis, Arthritis Rheumatol, 72, 1897, 10.1002/art.41403 Cyster, 2019, B Cell responses: cell interaction dynamics and decisions, Cell, 177, 524, 10.1016/j.cell.2019.03.016 Brekke, 2003, Therapeutic antibodies for human diseases at the dawn of the twenty-first century, Nat Rev Drug Discov, 2, 52, 10.1038/nrd984 Kuwana, 2005, Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis, Arthritis Rheum, 52, 2425, 10.1002/art.21232 Nihtyanova, 2009, A longitudinal study of anti-RNA polymerase III antibody levels in systemic sclerosis, Rheumatology, 48, 1218, 10.1093/rheumatology/kep215 Fukasawa, 2021, Single-cell-level protein analysis revealing the roles of autoantigen-reactive B lymphocytes in autoimmune disease and the murine model, Elife, 10, 10.7554/eLife.67209 Kowal-Bielecka, 2017, Update of EULAR recommendations for the treatment of systemic sclerosis, Ann Rheum Dis, 76, 1327, 10.1136/annrheumdis-2016-209909 Herrick, 2017, Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS), Ann Rheum Dis, 76, 1207, 10.1136/annrheumdis-2016-210503 Tanahashi, 2015, Disappearance of circulating autoantibodies to RNA polymerase III in a patient with systemic sclerosis successfully treated with corticosteroid and methotrexate, J Eur Acad Dermatol Venereol, 29, 1453, 10.1111/jdv.12512 Lima-Júnior, 2021, Autologous haematopoietic stem cell transplantation restores the suppressive capacity of regulatory B cells in systemic sclerosis patients, Rheumatology, 60, 5538, 10.1093/rheumatology/keab257 Farge, 2005, Analysis of immune reconstitution after autologous bone marrow transplantation in systemic sclerosis, Arthritis Rheumatism, 52, 1555, 10.1002/art.21036 Farge, 2017, Long-term immune reconstitution and T cell repertoire analysis after autologous hematopoietic stem cell transplantation in systemic sclerosis patients, J Hematol Oncol, 10, 21, 10.1186/s13045-016-0388-5 Tsukamoto, 2011, Analysis of immune reconstitution after autologous CD34+ stem/progenitor cell transplantation for systemic sclerosis: predominant reconstitution of Th1 CD4+ T cells, Rheumatology, 50, 944, 10.1093/rheumatology/keq414 Henes, 2017, Analysis of anti-topoisomerase I antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation, Rheumatology, 56, 451 Tony, 2011, Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID), Arthritis Res Ther, 13, R75, 10.1186/ar3337 Moazedi-Fuerst, 2015, Decrease in autoantibody titres during long-term treatment of scleroderma with rituximab: a promising surveillance marker of therapy?, Scand J Rheumatol, 44, 519, 10.3109/03009742.2015.1069888 Lafyatis, 2009, B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis, Arthritis Rheum, 60, 578, 10.1002/art.24249 Bosello, 2015, Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis, Semin Arthritis Rheum, 44, 428, 10.1016/j.semarthrit.2014.09.002 Ebata, 2021, Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial, Lancet Rheumatol, 3, e489, 10.1016/S2665-9913(21)00107-7 Hu, 2007, Immunization with DNA topoisomerase I induces autoimmune responses but not scleroderma-like pathologies in mice, J Rheumatol, 34, 2243 Yoshizaki, 2011, Immunization with DNA topoisomerase I and Freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling, Arthritis Rheum, 63, 3575, 10.1002/art.30539 Bergmann, 2021, X-linked inhibitor of apoptosis protein (XIAP) inhibition in systemic sclerosis (SSc), Ann Rheum Dis, 10.1136/annrheumdis-2020-219822 Mehta, 2016, Topoisomerase I peptide-loaded dendritic cells induce autoantibody response as well as skin and lung fibrosis, Autoimmunity, 49, 503, 10.1080/08916934.2016.1230848 Sugimoto, 1992, An antigenic determinant on human centromere protein B (CENP-B) available for production of human-specific anticentromere antibodies in mouse, Cell Struct Funct, 17, 129, 10.1247/csf.17.129 Yue, 2021, Transfer of PBMC from SSc patients induces autoantibodies and systemic inflammation in Rag2-/-/IL2rg-/- Mice, Front Immunol, 12, 10.3389/fimmu.2021.677970 Muryoi, 1991, Self reactive repertoire of tight skin mouse: immunochemical and molecular characterization of anti-topoisomerase I autoantibodies, Autoimmunity, 9, 109, 10.3109/08916939109006746 Muryoi, 1992, Antitopoisomerase I monoclonal autoantibodies from scleroderma patients and tight skin mouse interact with similar epitopes, J Exp Med, 175, 1103, 10.1084/jem.175.4.1103 Gentiletti, 2005, Demonstration of autoimmunity in the tight skin-2 mouse: a model for scleroderma, J Immunol, 175, 2418, 10.4049/jimmunol.175.4.2418 Shibata, 1993, Immunochemical and molecular characterization of anti-RNA polymerase I autoantibodies produced by tight skin mouse, J Clin Invest, 92, 984, 10.1172/JCI116675 Hatakeyama, 1996, Correlation between the concentration of serum anti-topoisomerase I autoantibodies and histological and biochemical alterations in the skin of tight skin mice, Cell Immunol, 167, 135, 10.1006/cimm.1996.0017 Servettaz, 2006, Anti-endothelial cell antibodies from patients with limited cutaneous systemic sclerosis bind to centromeric protein B (CENP-B), Clin Immunol, 120, 212, 10.1016/j.clim.2006.02.006 Yoshizaki, 2008, CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma, Am J Pathol, 172, 1650, 10.2353/ajpath.2008.071049 Pollard, 1997, The autoimmunity-inducing xenobiotic mercury interacts with the autoantigen fibrillarin and modifies its molecular and antigenic properties, J Immunol, 158, 3521, 10.4049/jimmunol.158.7.3521 Hultman, 1989, Anti-fibrillarin autoantibodies in mercury-treated mice, Clin Exp Immunol, 78, 470 Magna, 2016, The alarmin properties of DNA and DNA-associated nuclear proteins, Clin Ther, 38, 1029, 10.1016/j.clinthera.2016.02.029 Schiller, 2008, Autoantigens are translocated into small apoptotic bodies during early stages of apoptosis, Cell Death Different, 15, 183, 10.1038/sj.cdd.4402239 Robitaille, 2007, The nuclear autoantigen CENP-B displays cytokine-like activities toward vascular smooth muscle cells, Arthritis Rheum, 56, 3814, 10.1002/art.22972 Henault, 2006, DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients, Arthritis Rheum, 54, 963, 10.1002/art.21646 Prasad, 2021, Clinical and molecular features of anti-CENP-B autoantibodies, J Mol Pathol, 2, 281, 10.3390/jmp2040024 Muñoz, 2010, The role of defective clearance of apoptotic cells in systemic autoimmunity, Nat Rev Rheumatol, 6, 280, 10.1038/nrrheum.2010.46 Henault, 2004, Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis, Arthritis Rheum, 50, 3265, 10.1002/art.20515 Corallo, 2019, Antibodies against specific extractable nuclear antigens (ENAs) as diagnostic and prognostic tools and inducers of a profibrotic phenotype in cultured human skin fibroblasts: are they functional?, Arthritis Res Ther, 21, 152, 10.1186/s13075-019-1931-x Arcand, 2012, Heparin inhibits the interaction of DNA topoisomerase I/anti-topoisomerase I immune complexes with heparan sulfate on dermal fibroblasts, Arthritis Rheum, 64, 1632, 10.1002/art.33484 Kim, 2008, Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis, Arthritis Rheum, 58, 2163, 10.1002/art.23486 Eloranta, 2010, Type I interferon system activation and association with disease manifestations in systemic sclerosis, Ann Rheum Dis, 69, 1396, 10.1136/ard.2009.121400 Raschi, 2018, Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts, Arthritis Res Ther, 20, 187, 10.1186/s13075-018-1689-6 Raschi, 2020, Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis, Arthritis Res Ther, 22, 265, 10.1186/s13075-020-02360-3 Rahman, 1976, Appearance of IgG (Fc) receptor (s) on cultured human fibroblasts infected with human cytomegalovirus, J Immunol, 117, 253, 10.4049/jimmunol.117.1.253 Moradzadeh, 2021, Efficacy and safety of rituximab therapy in patients with systemic sclerosis disease (SSc): systematic review and meta-analysis, Clin Rheumatol, 10.1007/s10067-021-05698-4 Tang, 2020, Safety and efficacy of Rituximab in systemic sclerosis: a systematic review and meta-analysis, Int Immunopharmacol, 83, 10.1016/j.intimp.2020.106389 Borrirukwisitsak, 2021, Efficacy and safety of rituximab on lung and skin involvement in systemic sclerosis: a systematic review and metaanalysis, Clin Rheumatol, 10.1007/s10067-020-05542-1 Roth, 2013, Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis, J Clin Invest, 123, 1773, 10.1172/JCI65292 Holers, 2018, Rheumatoid arthritis and the mucosal origins hypothesis: protection turns to destruction, Nat Rev Rheumatol, 14, 542, 10.1038/s41584-018-0070-0 Lepri, 2022, Systemic sclerosis association with malignancy, Clin Rev Allergy Immunol, 10.1007/s12016-022-08930-4 Nandiwada, 2016, Ethnic differences in autoantibody diversity and hierarchy: more clues from a US cohort of patients with systemic sclerosis, J Rheumatol, 43, 1816, 10.3899/jrheum.160106